Supplementary

Table S1 Inclusion and exclusion criteria for donation

Inclusion criteria	Exclusion criteria			
Age >18 years <70 years ⁺	History of viral disease			
Time of death <24 h at processing ⁺	Presence or suspicion of degenerative neurological diseases of possible infectious origin			
	Active and uncontrolled infection at the time of donation; includes systemic bacterial, viral, parasitic or fungal infection, or localized infection in the tissues to be used			
	Presence or history of malignant disease, except histologically proven primary basal cell carcinoma, non-metastatic primary brain tumor, carcinoma in situ of the uterine cervix that has been cured for more than 10 years			
	History of systemic autoimmune disease, or any immunosuppressive treatment			
	Ingestion or exposure to any toxic			
	Use of pituitary growth hormone of human origin			
	History of dura mater, cornea or sclera transplantation			
	Unknown cause of death. Except when an autopsy can be performed and shows that there is no reason for exclusion			
	History of a disease of unknown etiology			
	Presence of risk factors for disease transmission, taking into account travel history and local prevalence of infectious diseases			
	Xenotransplantation recipients			
	Recent history of vaccination with a live attenuated virus where a risk of transmission is considered to exist			
	Indications that test results of donor blood samples will be invalid because of hemodilution, according to validated specifications where a pretransfusion sample is not available or treatment with immunosuppressive agents			
	Presence of social behavioral factors considered risk determinants for HIV, HBV and HCV			
*, criteria for the purpose of this research. HIV, human immunodeficiency virus; HBV, hepatitis B virus; HCV, hepatitis C virus.				

[,] criteria for the purpose of this research. HIV, human immunodeficiency virus; HBV, hepatitis B virus; HCV, hepatitis C virus.

Table S2 Antibodies used for MSC immunophenotyping

Target	Isotype	Fluorochrome	Clone number	Purpose
CD90	lgG1κ	FITC	5E10	Positive marker
CD105	lgG1κ	PerCP-Cy5.5	266	Positive marker
CD73	lgG1κ	APC	AD2	Positive marker
CD34	IgG2aк	PE	581	Exclusion marker
CD11b	IgG2aк	PE	ICRF44	Exclusion marker
CD19	IgG2aк	PE	HIB19	Exclusion marker
CD45	IgG2aк	PE	HI30	Exclusion marker
HLA-DR	IgG2aк	PE	G46-6	Exclusion marker

All the antibodies were supplied in the Stemflow hMSC Analysis Kit (Becton Dickinson Pharmingen, USA). MSC, mesenchymal stromal cell; HLA, human leukocyte antigen; HLA-DR, isotype of HLA clase II; hMSC, human mesenchymal stromal cells.